Shares of Nuformix plc (LON:NFX – Get Free Report) shot up 6.7% during trading on Wednesday . The company traded as high as GBX 0.08 ($0.00) and last traded at GBX 0.08 ($0.00). 6,245,796 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 52,332,500 shares. The stock had previously closed at GBX 0.08 ($0.00).
Analysts Set New Price Targets
Separately, Canaccord Genuity Group initiated coverage on shares of Nuformix in a report on Tuesday. They set a “buy” rating and a GBX 293 ($3.80) target price for the company.
Read Our Latest Research Report on NFX
Nuformix Price Performance
Nuformix (LON:NFX – Get Free Report) last posted its quarterly earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) earnings per share for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Stories
- Five stocks we like better than Nuformix
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
- How to Calculate Return on Investment (ROI)
- Cybersecurity Stocks Surge as $32B Deal Reshapes the Industry
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
